91ÊÓƵרÇø

²ú³Ü²µ³Ü´Ç£¬³ú³ó±ð°ì³Ü²¹²Ô³¦³ó±ð»å±ð°ì´Ç²Ô²µÂá¾±²¹²Ô²â±ð²â´Ç³Ü°ì±ð±ç³Ü²¹²Ô°ì±ð»å¾±²¹²Ô»å±ð²ú³Ü´Ú±ð²Ô£¬²ú¾±°ù³Ü£¬»å²¹»å²¹´Ç580²õ³ó±ð²Ô²µ»å±ð³ó´Ç³Ü²ú±ð¾±³æ¾±²¹²Ô²µ°ù´Ç²Ô²µÂá¾±£¬°ì±ð³Ù´Ç²Ô²µ²õ³ó¾±²õ³ó´Ç³Ü²Ô²¹28/24/20²â¾±²Ô²µ³¦³Ü²Ô»å±ð³æ¾±²Ô²µ±ô¾±³æ¾±²¹²Ô²µ£¬³ú²¹¾±Âá¾±²¹²õ³ó²¹²Ô²µ²â¾±³Ù²¹´Ç»å¾±²¹´Ç²â³Ü³ú³ó³Ü²¹²Ô²µ²ú±ð¾±¡¢²â¾±²µ±ð»å±ð²Ô²µ²õ³ó²¹²Ô±ô±¹³æ¾±²Ô²µ²õ³ó³Ü²¹²Ô²µÂá¾±²¹²Ô²ú±ð¾±²ú²¹´Ç¡£²ú¾±²Ô²µ±è±ð¾±²ú±ð¾±±ô¾±²¹´Ç»å¾±²¹²Ô»å´Ç²Ô²µ³ó´Ç³Ü·É±ð¾±³¾±ð²Ô¡¢»å¾±²¹²Ô»å´Ç²Ô²µ³ó´Ç³Ü·É±ð¾±³¾±ð²Ô·É±ð¾±³ú³ó¾±Âá¾±²â¾±²µ´Ç²Ô²µ²Ô±ð²Ô²µ¡£2²â³Ü±ð24°ù¾±£¬³ú³ó´Ç²Ô²µ²µ³Ü´Ç°ù±ð²Ô³¾¾±²Ô²â¾±²Ô³æ¾±²Ô²µ´Ú²¹²ú³Ü³æ¾±²¹´Ç³æ¾±³¦³ó±ð²Ô²µ£¬·É±ð¾±±è±ð¾±²â³Ü³ó±ð´Ú²¹³ú³ó²¹²Ô³ú³ó³Ü´Ú²¹²Ô²µ³ú³Ü±ô¾±²Ô²õ³ó¾±³¦³ó²¹²Ô²µ£¬³¦³ÜÂá¾±²Ô´Ú²¹²Ô²µ»å¾±³¦³ó²¹²Ô²õ³ó¾±³¦³ó²¹²Ô²µ±è¾±²Ô²µ·É±ð²ÔÂá¾±²¹²Ô°ì²¹²Ô²µ´Ú²¹³ú³ó²¹²Ô£¬°ù±ð²Ô³¾¾±²Ô²â¾±²Ô³æ¾±²Ô²µ¡¢²â¾±²Ô²ú²¹´ÇÂá¾±²¹²Ô³ó³Ü¾±±ç¾±³¦²¹´Ç±ô¾±²¹´Ç¡·£©¡£

±ù(µþ¾±²Ô²µ)Àä(³¢±ð²Ô²µ)µÄ(¶Ù±ð)ºÓ(±á±ð)Ë®(³§³ó³Ü¾±)˲(³§³ó³Ü²Ô)¼ä(´³¾±²¹²Ô)ÑÍ(³Û²¹²Ô)û(²Ñ±ð¾±)Ëý(°Õ²¹)µÄ(¶Ù±ð)Ë«(³§³ó³Ü²¹²Ô²µ)ÍÈ(°Õ³Ü¾±)Éí(³§³ó±ð²Ô)Ìå(°Õ¾±)£¬Õý(´Ü³ó±ð²Ô²µ)µ±(¶Ù²¹²Ô²µ)ºÓ(±á±ð)Ë®(³§³ó³Ü¾±)˳(³§³ó³Ü²Ô)±±(µþ±ð¾±)ÑÍ(³Û²¹²Ô)û(²Ñ±ð¾±)Ëý(°Õ²¹)µÄ(¶Ù±ð)ÄÔ(±·²¹´Ç)´ü(¶Ù²¹¾±)ʱ(³§³ó¾±)£¬»Ð(±á³Ü²¹²Ô²µ)ã±(´Ü³Ü´Ç)¼ä(´³¾±²¹²Ô)Ëý(°Õ²¹)Ìý(°Õ¾±²Ô²µ)µ½(¶Ù²¹´Ç)Éí(³§³ó±ð²Ô)ºó(±á´Ç³Ü)´«(°ä³ó³Ü²¹²Ô)À´(³¢²¹¾±)ĸ(²Ñ³Ü)Ç×(²Ï¾±²Ô)µÄ(¶Ù±ð)º°(±á²¹²Ô)½Ð(´³¾±²¹´Ç)ºÍ(±á±ð)¿Þ(°­³Ü)Æü(²Ï¾±)¡£

houdianshiyizuomingdaidejianzhu£¬zhongdianguanzhuzhuchujingmeideshidiao¡£ruhequfenfeidianxingCMLyuqitagusuizengzhixingzhongliuyuanchuang2020-09-12 17:53¡¤yimaitongxueyekezuozhe£ºlanjingxiaohubenwenweizuozheshouquanyimaitongfabu£¬weijingshouquanqingwuzhuanzai¡£feidianxingmanxingsuixibaixuebing(aCML)£¬BCR-ABL1(£­)£¬shiyizhonghanjiandexueyeexingzhongliu£¬shuyuWHOgusuizhongliufenleizhongdegusuizengshengyichang/gusuizengzhixingzhongliu(MDS/MPN)¡£aCMLzuichubeimingmingwei¡°feidianxing¡±xingshidemanxingsuixibaixuebing(CML)£¬jishinianlaiaCMLdezhenduanbiaozhunfashengliaoxianzhubianhua¡£raner£¬aCMLdezhenduanquefatezhengxing£¬duiqifenzijiyintupuderiyiliaojieyouzhuyuqufenaCMLyuqitaMDS/MPNheMPNs£¬yibianzaoqiqidongzhiliaohegaishanyuhou¡£aCMLdelinchuanghexingtaibiaoxingaCMLhuanzhebiaoxianchugusuizengshengtezheng£¬baokuobaixibaozengduohepizhongda£¬kebanyoupinxuehexuexiaobanjianshao¡£WBCjishu¡Ý13¡Á109/L¡£waizhouxuezhongcunzaizhishao10%deweichengshulixibao£¨baokuozaoyoulixibao¡¢zhongyoulixibaohewanyoulixibao£©£¬yizhongdulixibaoshengchengzhangaiweitezheng¡£bucunzaidanhexibaozengduo£¨waizhouxuedanhexibao2%£©¡£xibaohuaxueranse£¬rufeiteyixingzuomei(NSE)youzhuyuzaiyinanbinglizhongjiancedanhexibao¡£lingyigegengzhuguandexingtaixuequbieshiaCMLcunzaigengyanzhongdelixibaofayubuliang£¬jinguanquefapinggufayubuliangyanzhongchengdudejutizhinan¡£xuyaojinxingtieranseyipaichubanyouhuanxingtieliyouxibaohexuexiaobanzengduodeMDS/MPN-RS-T¡£zaiyizengzhitezhengweizhu£¬qieyizhongxinglixibaoweizhudehuanzhezhong£¬CSF3RtubianyingqianglietishiCNL¡£qufenaCMLyuMDS/MPN-Ujiaoweikunnan¡£aCMLhuanzhedezhongweiWBCjishuxianzhushenggao£¬danfeijueduitezheng¡£chixuxingdanhexibaozengduotishiCMML¡£TET2+SRSF2tubianduiCMMLjuyouxiangduiteyixing£¬jinguanliangzhezaiaCMLzhongjunkejian¡£yizhongxindeaCMLzhenduanliuchengxiaojieyouyufabinglvdi¡¢zhenduanbiaozhunbuduangengxinhequefafenziyichuanxuedelijie£¬feidianxingmanxingsuixibaixuebingyizhishiyizhongnanyizhenduandeMDS/MPN¡£suizhuoduijiyinzudashujudebuduanwajue£¬yifaxianSETBP1heETNK1defanfutubianduiaCMLyoutishizuoyong£¬keyijieheshiyanshihexingtaixuejieguolaiqufenaCMLheqitafeichengyinxinggusuizengzhixingzhongliu¡£ranertubiandetongshifashengshifouhuigaibianaCMLdejibingbiaoxinghezhiliaofanyingshangbumingque¡£cankaowenxian£º1. Orazi A, Bennett JM, Bain BJ, et al. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. pp. 87¨C89.2. Kantarjian HM, Keating MJ, Walters RS, et al. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 1986; 58:2023¨C2030.3. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19:2915¨C2926.4. Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. Ther Adv Hematol 2015; 6:308¨C312.5. Sadigh S, Hasserjian RP, Hobbs G. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. Curr Opin Hematol. 2020;27(2):122-127.6. Itonaga H, Ota S, Ikeda T, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan. Leuk Res 2018; 75:50¨C57.7. Meggendorfer M, Haferlach T, Alpermann T, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica 2014; 99:e246.8. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123:2645 -2651.9. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 2017; 92:542¨C548.10. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev 2019; 33:74¨C81.11. Faisal M, Stark H, Busche G, € et al. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. Cancer Med 2019; 8:742¨C750.12. Zhang H, Wilmot B, Bottomly D, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 2019; 134:867¨C879.13. Hasserjian RP. Illuminating neutrophilic myeloid neoplasms. Blood 2019; 134:846¨C848.14. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113¨C122.15. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123:3574¨C3577.16. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080¨C3088.

323 196 71025

³¤´ï 30¶àÄêµÄ Microsoft Office Æ·ÅÆÏÂÔ¿ªÊ¼µ­³ö²¢¸ü¸ÄÃû×Ö2022-10-14 01:39¡¤µçÆøµÀ148˵µ½ Microsoft µÄ²úÎïµÄÖªÃû¶È£¬Windows Æ·Åƿ϶¨ÊÇÊ×룬¶ø Microsoft Office ÏàÐÅ»áÊÇλÁеڶþ¡£Microsoft Ðû²¼ Microsoft Office ½«»áÖØÐÂÃüÃûΪ Microsoft 365£¬Í»³öËüÔÚÉú²úÁ¦¼°Ð­×÷·½ÃæµÄ²»Ò»Ñù¡£Word¡¢Excel¡¢PowerPoint¡¢Outlook µÈºËÐÄ Microsoft Office Ó¦Óò»»áÒòΪ¸ÄÃû¶øÏûʧ£¬Ö»ÊÇ»á¹éÄÉÓÚ Microsoft 365 Ö®ÖС£ÊÂʵÉÏ£¬Microsoft ÒÑÓÚ 2020 Äê 4 ÔÂÒѽ«¶©ÔÄ°æ Office 365 ¸ÄÃûΪ Microsoft 365¡£Î´À´ÊýÔ£¬Office.com¡¢Office µÄÊÖ»ú£¯Æ½°å Apps ¼°ÔÚ Windows ÉÏʹÓÃµÄ Office Ó¦ÓÃÈí¼þ³ÌʽҲ¸ÄÃûΪ Microsoft 365£¬²¢»»ÉÏеÄͼʾ¼°Íâ¹Û£¬Í¬Ê±ÌṩһЩй¦ÄÜ£¬ÀýÈçеķ¶±¾¡¢Ó¦ÓÃÄ£×é¡¢Feed¡¢±êÇ©µÈµÈ¡£Microsoft ÔÚ¹Ù·½ Microsoft 365 FAQ ÖÐÖ¸³ö£¬Office.com ½«ÓÚ 11 ÔÂÕýʽ¸ü»»Éè¼Æ¼°¸Ä Logo¡£ÖÁÓÚ Windows¡¢iOS¡¢iPadOS¡¢Android Ó¦ÓóÌʽÔò»áÔÚ 2023 Äê 1 Ô¸ü¸ÄÃû³Æ¡£ÖÁÓÚ Microsoft Office µÄÆ·ÅÆÔò»áÔÚÒ»´ÎÐÔ¹ºÂòµÄ Office 2021 ¼° Office LTSC ¼Æ»®ÖгöÏÖ¡£ÒÀÍÐÇå±±µÈ¸ßУʵʩ¡°Ð½»ð¹²È¼¡±¼Æ»®¡¶ÃÀÀöµÄ¹ÃÄïÃâ·ÑÊÓƵ¹Û¿´È«¼¯¸ßÇå¡·Ep. 74ÔÚÏß¹Û¿´ - À¶¹â...

½ØÖÁÄ¿Ç°СÃ×¼¯ÍÅÃÀ¹ÉÕÇ·ù×î¸ß´ïµ½9.61%¿É¼û×ʱ¾¶ÔСÃ×Æû³µµÄ¿´ºÃÔÚÆ»¹ûÆû³µÐû¸æ·ÅÆúÖйúÐÂÄÜÔ´Æû³µÊг¡ÄÚ¾íµÄ״̬ÏÂÀ×¾ü»¹Äܶ¥×¡Ñ¹Á¦ÍƳöСÃ׳§±«7ȷʵÁîÈËÅå·þ

ÉùÃ÷£º¸ÃÎĹ۵ã½ö´ú±í×÷Õß±¾ÈË£¬ËѺüºÅϵÐÅÏ¢·¢²¼Æ½Ì¨£¬ËѺü½öÌṩÐÅÏ¢´æ´¢¿Õ¼ä·þÎñ¡£